What is the address of FEBELFARMA?

The registered office of FEBELFARMA is located at Eigenlostraat 1, 9100 Sint-Niklaas.

Is FEBELFARMA still active?

Yes. According to the CBE (29 October 2026) FEBELFARMA is active, legal situation “Normale toestand”, started on 23 December 2002.

Is FEBELFARMA registered on Peppol?

Yes, FEBELFARMA is registered on the Peppol network with ID 0208:0479127936.

What is the enterprise number of FEBELFARMA?

The enterprise number of FEBELFARMA is BE0479127936.

When was FEBELFARMA founded?

FEBELFARMA was founded on 23 December 2002.

Who are the directors of FEBELFARMA?

According to the 2025 annual accounts, the directors of FEBELFARMA are: Alexo BV, Aristo BV, Eric Van Nueten.

Is FEBELFARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 December 2002; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did FEBELFARMA make in 2025?

FEBELFARMA posted a profit after taxes of € 45,753 in financial year 2025.

What is the revenue of FEBELFARMA?

In its most recent annual accounts (2025), FEBELFARMA reported revenue of € 59,365.

FEBELFARMA (Private Limited) - Sint-Niklaas

Q: What does FEBELFARMA do?

FEBELFARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 23 December 2002, 1 establishment.

Dossier FEBELFARMA, printed on 29 October 2026 from databakkes.be/en/0479127936/febelfarma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FEBELFARMA from Sint-Niklaas, company number BE0479127936, closed financial year 2025 with a result of € 45,753 after tax. For that financial year FEBELFARMA recorded revenue of € 59,365 and equity of € 2 million. Compared with financial year 2024, the result moved from € 608,557 to € 45,753. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 2 million

▲ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 45,753

▼ 92% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.5 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 11,229

▲ € 8,562 vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 100 days on average.

Taxes

€ 17,953

▲ € 14,772 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 15,531 Revenue 2022: € 15,531 First fiscal year in the series	€ 29,774 Revenue 2023: € 29,774 ▲ 92% vs 2022 (€ 15,531) Favourable step	€ 40,015 Revenue 2024: € 40,015 ▲ 34% vs 2023 (€ 29,774) Favourable step	€ 59,365 Revenue 2025: € 59,365 ▲ 48% vs 2024 (€ 40,015) Favourable step	▲ 48%
Profit after taxes	€ 40,155 Profit after taxes 2022: € 40,155 First fiscal year in the series	€ 24,259 Profit after taxes 2023: € 24,259 ▼ 40% vs 2022 (€ 40,155) Unfavourable step	€ 608,557 Profit after taxes 2024: € 608,557 ▲ € 584,298 vs 2023 (€ 24,259) Favourable step	€ 45,753 Profit after taxes 2025: € 45,753 ▼ 92% vs 2024 (€ 608,557) Unfavourable step	▼ 92%
Equity	€ 1,349,142 Equity 2022: € 1,349,142 First fiscal year in the series	€ 1,373,401 Equity 2023: € 1,373,401 ▲ 2% vs 2022 (€ 1,349,142) Favourable step	€ 1,981,958 Equity 2024: € 1,981,958 ▲ 44% vs 2023 (€ 1,373,401) Favourable step	€ 2,027,711 Equity 2025: € 2,027,711 ▲ 2% vs 2024 (€ 1,981,958) Favourable step	▲ 2%
Total debts	€ 9,325 Total debts 2022: € 9,325 First fiscal year in the series	€ 11,259 Total debts 2023: € 11,259 ▲ 21% vs 2022 (€ 9,325) Unfavourable step	€ 14,518 Total debts 2024: € 14,518 ▲ 29% vs 2023 (€ 11,259) Unfavourable step	€ 29,699 Total debts 2025: € 29,699 ▲ 105% vs 2024 (€ 14,518) Unfavourable step	▲ 105%
Retained profit	€ 798,566 Retained profit 2022: € 798,566 First fiscal year in the series	€ 822,825 Retained profit 2023: € 822,825 ▲ 3% vs 2022 (€ 798,566) Favourable step	€ 1,431,382 Retained profit 2024: € 1,431,382 ▲ 74% vs 2023 (€ 822,825) Favourable step	€ 1,477,135 Retained profit 2025: € 1,477,135 ▲ 3% vs 2024 (€ 1,431,382) Favourable step	▲ 3%
Balance sheet total	€ 1,358,466 Balance sheet total 2022: € 1,358,466 First fiscal year in the series	€ 1,384,660 Balance sheet total 2023: € 1,384,660 ▲ 2% vs 2022 (€ 1,358,466) Unchanged	€ 1,996,476 Balance sheet total 2024: € 1,996,476 ▲ 44% vs 2023 (€ 1,384,660) Unchanged	€ 2,057,410 Balance sheet total 2025: € 2,057,410 ▲ 3% vs 2024 (€ 1,996,476) Unchanged	▲ 3%

Key figures of FEBELFARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FEBELFARMA?

What happened at FEBELFARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 45,753 (▼ 92% vs 2024). filed late Source: NBB ↗
Apr 28, 2003 New establishment in Sint-Niklaas. KBO
Dec 23, 2002 Start of the company according to the CBE. KBO

In short

From € 40,155 profit in 2022 to € 45,753 profit in 2025.

Paid € 35,387 in corporate taxes since 2022.

Best year ever: 2024, with € 608,557 profit.

Pays suppliers within 100 days on average.

Original PDFs at the National Bank ↗

Management

FEBELCO 99.8%

The stake of FEBELCO comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FEBELFARMA

Pharmacie Coloniale 25%

Axone Pharma 0.1%

Livlina 0%

Behind FEBELFARMA are Alexo BV, Aristo BV and Eric Van Nueten. The shares are held by FEBELCO (99.8%). It owns 25% of Pharmacie Coloniale, 0.1% of Axone Pharma and 0% of Livlina itself.

Directors

According to the 2025 annual accounts

Alexo BV

Managing director · represented by Olivier Delaere

Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more

Aristo BV

Chairman of the board · represented by Frank Coene

Also active at: LIVLINA, FEBELCO, FEBELCOFONDS, AXONE PHARMA, LIVLINA TRANSPORT

Eric Van Nueten

Director

Also active at: APOTHEEK MOLENVELD, FEBELCO, FEBELCOFONDS, EVN CONSULTING, E.V.N. PHARMA

Shareholders

FEBELCO

99.8%

Participations

Pharmacie Coloniale

25%

Axone Pharma

0.1%

Livlina

Establishments

Establishment units

Physical locations of this company

Registered office

Eigenlostraat 1

9100 Sint-Niklaas

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

FEBELCO same network

€ 1.8 billion revenue · 2025

FEBELCOFONDS same network

MEDIPIM same network

€ 810,044 gross margin · 2025

Febelco Group Pillar Two

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0479.127.936

VAT number

BE 0479.127.936

Registered office

Eigenlostraat 1, 9100 Sint-Niklaas

Names & denominations

FEBELFARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 December 2002

Peppol

Active · Active since 23 Dec 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Overige vormen van onderwijs

View on CBE Public ↗ Annual accounts (NBB) ↗

FEBELFARMA

Financials

What happened to FEBELFARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions